Lung Biotechnology Public Benefit Corporation
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 112
- Registration Number
- NCT03657095
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Beverly Hills, California, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
Beraprost-314d Added-on to Tyvaso® (BEAT)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 273
- Registration Number
- NCT01908699
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center Heart Institute, Beverly Hills, California, United States
🇺🇸Allianz Research Institute Inc., Fountain Valley, California, United States
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Lung Biotechnology PBC
- Registration Number
- NCT01458236
Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 31
- Registration Number
- NCT00990314
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Midwest Heart Foundation - Advocate Medical Group, Oakbrook Terrace, Illinois, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 36
- Registration Number
- NCT00989963
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Edward Heart Hospital, Naperville, Illinois, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
- Prev
- 1
- 2
- Next